5F-MDMP-2201,cas:1971007-88-1

14680-51-4 =Metonitazene
14188-81-9 =/Isotonitazene
119276-01-6 =Protonitazene (hydrochloride)
95810-54-1 =Butonitazene
111982-50-4 =2FDCK
802855-66-9 =EUtylone
14176-50-2 =Tiletamine
1971007-88-1 =5F-MDMP-2201
612526-40-6 =Flubromazolam
14530-33-7 =APVP
28910-91-0 =Flualprazolam
13605-48-6 =pmk
1823274-68-5 =PMK
1387636-19-2 =BMDP
1314093-06-5 =PMK
16648-44-5 =BMK
60996-94-3 =Dipyanone
1715016-75-3 =5fadb/5fdck
1354631-33-6 =4F-mph
40054-69-1 = Etizolam
40054-73-7 =Deschloroetizolam
2647-50-9 =Flubromazepam
39243-02-2 =Pyrazolam / Flubromazolam
94-15-5 =/Dimethocaine
71368-80-4 =Bromazolam

5F-MDMB-PICA is a designer drug and synthetic cannabinoid.[1][2][3][4][5] In 2018, it was the fifth-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.[6]

5F-MDMB-PICA is a potent agonist of both the CB1 receptor and the CB2 receptor with EC50 values of 0.45 nM and 7.4 nM, respectively.[7]

In the United States, 5F-MDMB-PICA was temporarily emergency scheduled by the DEA in 2019.[8] In December 2019, the UNODC announced scheduling recommendations placing 5F-MDMB-PICA into Schedule II.[9] In the United States 5F-MDMB-PICA was made a permanent Schedule I Controlled Substance nationwide on April 7, 2022.[10]